Oncoinvent is a clinical-stage radiopharmaceutical developer with a single lead asset, Radspherin — microspheres emitting short-range alpha radiation (Radium-224) intended to treat micrometastatic disease in the peritoneal cavity, with ovarian cancer as the lead indication. As a pre-commercial biotech it has no revenue, an operating loss of ~NOK 158M per year, and ~NOK 180M of cash against zero debt. Invested capital is negative (cash exceeds equity), so ROIC and economic profit are not meaningful and are reported as n/a — the right lens here is cash runway, pipeline catalysts and dilution risk, not return on capital.
The setup is binary. The ~NOK 180M cash gives roughly a 5.5-quarter runway into 2027 — which the company itself says will NOT fund development through to a conclusion, so a capital raise is likely, probably around the pivotal-track ovarian-cancer interim read-out expected near end-2026. The stock trades close to net cash (enterprise value ~NOK 16M), so the market currently ascribes little value to the pipeline; a positive Phase 2 read-out could re-rate it sharply, while a setback or a dilutive raise would hit hard. This is a speculative, catalyst-driven situation, not a fundamentals/ROIC investment.
Return-on-capital valuation does not apply (pre-revenue, negative invested capital). The relevant frame is balance-sheet + optionality: enterprise value ~NOK 16M against ~NOK 180M net cash means the market prices the Radspherin pipeline at close to zero, with a ~5.5-quarter runway as the clock.
Base NOK 44 (≈ net cash + a small pipeline option, near the current price); bull NOK 90 if the end-2026 ovarian-cancer interim read-out is positive and re-rates the Radspherin opportunity; bear NOK 22 if a dilutive raise and/or a trial setback halves the equity.
Reverse-DCF panel unavailable: non-positive nopat.
| Scenario | 24m target | Upside | Prob. | Driver |
|---|---|---|---|---|
| Bull | NOK 90 | +106% | 30% | Positive end-2026 ovarian-cancer interim re-rates Radspherin |
| Base | NOK 44 | +1% | 35% | ≈ net cash + small pipeline option |
| Bear | NOK 22 | -50% | 35% | Dilutive raise and/or trial setback halves the equity |
| Prob-weighted | NOK 50 | +15% | 100% | Scenario-weighted expected value |
The end-2026 interim is the binary value catalyst.
~NOK 180M cash, ~5.5-quarter runway into 2027 — the survival clock.
Differentiated Ra-224 microsphere approach with multi-indication potential if validated.
EV ~NOK 16M — the pipeline is priced at close to zero, so success is asymmetric.
Oncoinvent is a pre-revenue, single-asset clinical radiopharma priced as a near-cash shell (EV ~NOK 16M vs ~NOK 180M net cash), with a ~5.5-quarter runway and a binary end-2026 ovarian-cancer read-out ahead — and a dilutive raise likely. ROIC/EP are not applicable. HOLD / avoid for fundamentals-anchored capital; base NOK 44.
Only a sized, risk-aware speculative position on the Phase 2 catalyst fits — this is a binary, dilution-exposed situation, not a return-on-capital investment.
Every adjustment traces to the cited note/page in the source filing — click to open it there. Annual report / 10-K: 📄 open
| Adjustment / figure | Value | Source | Why mttssn treats it this way |
|---|---|---|---|
| -158 | — | ||
| -155 | — | ||
| 28.069 | — | ||
| 180 | — | ||
| 27.125 | — | ||
| -130 | — | ||
| -0.119 | — | ||
| -105 | — | ||
| -69.721 | — | ||
| 146 | — | ||
| 0 | — | ||
| 4.478 | — | ||
| 141 | — | ||
| 51.271 | — | ||
| 43.7 | — |
How the mttssn view has evolved — each prior dated note is preserved.